{"id":61377,"date":"2025-06-05T10:06:46","date_gmt":"2025-06-05T08:06:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/"},"modified":"2025-06-05T10:06:46","modified_gmt":"2025-06-05T08:06:46","slug":"fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/","title":{"rendered":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research"},"content":{"rendered":"
\n

TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD<\/a>–Fujirebio, a leading innovator in in-vitro<\/i> diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio\u2019s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cInfectious diseases remain one of the greatest global health challenges of our time,\u201d says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. \u201cBy working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.\u201d<\/p>\n

\n\u201cThis collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio\u2019s global IVD expertise and Fluxus\u2019 ultrasensitive detection systems with Stanford\u2019s world-renowned research,\u201d says Dr. Peter Wagner, President and CEO of Fluxus, Inc. \u201cWe are thrilled to be working with Stanford University\u2019s prestigious infectious disease experts.\u201d<\/p>\n

\nAbout Fujirebio<\/b><\/p>\n

\nFujirebio, a member of H.U. Group Holdings Inc., is an R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information, please visit http:\/\/www.fujirebio.com<\/a>.<\/p>\n

\nAbout Fluxus<\/b><\/p>\n

\nFluxus is an industry leader and innovator in optofluidic technologies that develops ultrasensitive detection systems and assay solutions to advance the diagnosis, monitoring, and treatment of diseases.<\/p>\n

Contacts<\/b> <\/p>\n

\nH.U. Group Holdings, Inc.
\n
For media:
\n
Public Relations Section, Public Relations\/Sustainability Dept.
\n
Phone: +81-3-6279-0884 \u3000
\n
Email: pr@hugp.com<\/a><\/p>\n

\nFor investors and analysts:
\n
IR\/SR Dept.
\n
Phone: +81-3-6279-0926\u3000
\n
Email: ir@hugp.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD–Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio\u2019s Silicon Valley … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61377","6":"format-standard","7":"category-industry"},"yoast_head":"\nFujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD–Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio\u2019s Silicon Valley ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T08:06:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research\",\"datePublished\":\"2025-06-05T08:06:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/\"},\"wordCount\":417,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250604871027\\\/en\\\/2489800\\\/22\\\/3-1_01_FRlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/\",\"name\":\"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250604871027\\\/en\\\/2489800\\\/22\\\/3-1_01_FRlogo.jpg\",\"datePublished\":\"2025-06-05T08:06:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250604871027\\\/en\\\/2489800\\\/22\\\/3-1_01_FRlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250604871027\\\/en\\\/2489800\\\/22\\\/3-1_01_FRlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/","og_locale":"en_US","og_type":"article","og_title":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend","og_description":"TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD–Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio\u2019s Silicon Valley ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-05T08:06:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research","datePublished":"2025-06-05T08:06:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/"},"wordCount":417,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/","url":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/","name":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg","datePublished":"2025-06-05T08:06:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250604871027\/en\/2489800\/22\/3-1_01_FRlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fujirebio-announces-strategic-collaboration-with-stanford-medicine-to-advance-infectious-disease-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61377"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61377\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}